Prakt. lékáren. 2014; 10(4): 137-142

Drug-induced kidney injury

Katarína Dobrucká
Oddělení klinické farmacie, Nemocnice na Homolce, Praha

Iatrogenic nephrotoxicity is the cause of acute kidney injury (AKI) in 19 to 25 percent of cases of the overall rate of renal failure.

In critically-ill patients with the presence of risk factors, the rate of medication-related AKI is reported to be 20–30%, of which 6%

require dialysis treatment. The occurrence of drug-induced AKI in elderly patients is as much as 60%. Iatrogenic AKI is associated

with a longer hospital stay, increased treatment costs, and higher mortality rate. The article presents an overview of the mechanisms

of iatrogenic nephrotoxicity with recommendations on preventive strategies when administering drugs with nephrotoxic potential;

the options of prevention or early diagnosis of kidney injury by identifying specific biomarkers; the use of computer applications

with a focus on improving safety in drug prescription; as well as the advantages of team collaboration of specialists (physician, clinical

pharmacist, nurse).

Keywords: drugs, nephrotoxicity

Published: August 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dobrucká K. Drug-induced kidney injury. Praktické lékárenství. 2014;10(4):137-142.
Download citation

References

  1. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008; 36(4 Suppl.): S216-S223. Go to original source... Go to PubMed...
  2. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: Recognition and prevention strategies. Crit Care Med 2010; 38(6 Suppl.): S169-S174. Go to original source... Go to PubMed...
  3. Merta M. Nefrotoxicita léků - co je nového? Medicína po promoci 2008; 9(1 Suppl.): 54-60.
  4. De Broe ME. Drug-induced nephropathies. In: Clinical nephrology. Oxford: Oxford University Press; 2005: 2581-2598.
  5. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, lenght of stay, and cost in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370. Go to original source... Go to PubMed...
  6. Decloedt E, Maartens G. Drug-induced renal injury. CME 2011; 29(6): 252-255.
  7. Chittineni H, Miyawaki N, Gulipelli S, et al. Risk for acute renal failure in patients hospitalized for decompensated congetive heart failure. Am J Nephrol 2007; 27: 55-62. Go to original source... Go to PubMed...
  8. Cruz CS, Cruz LS, Silva GR, et al. Incidence and predictors of development of acute renal failure related to treatment of acute renal failure related to treatment of congestive heart failure with ACE inhibitors. Nephron 2007; 105: c77-83. Go to original source... Go to PubMed...
  9. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nature clinical practice Nephrology 2006; 2(2): 80-91. Go to original source... Go to PubMed...
  10. Lamas S. Cellular mechanisms of vascular Indry mediated by calcineurin inhibitors. Kidney Int 2005; 68: 898-907. Go to original source... Go to PubMed...
  11. Xiaoqing G, Chike N. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleveland Clinic Journal of Medicine 2002; 69(4): 289-312. Go to original source... Go to PubMed...
  12. Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus associated thrombotic microangiopathy. Am J Kidney Dis 2000; 36: 844-850. Go to original source... Go to PubMed...
  13. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-790. Go to original source... Go to PubMed...
  14. Perazella MA. Drug-induced nephropathy: an update. Expert Opin Drug Saf 2005; 4(4): 689-706. Go to original source... Go to PubMed...
  15. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005; 351(1-2): 31-47. Go to original source... Go to PubMed...
  16. Barett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulation. Clin Ther 2003; 25: 1295-1320. Go to original source... Go to PubMed...
  17. Saliba F, Dupont B. Renal impairment and Amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008; 46(2): 97-112. Go to original source... Go to PubMed...
  18. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49: S37-S41. Go to original source... Go to PubMed...
  19. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 2001; 322: 579-582. Go to original source... Go to PubMed...
  20. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49: S31-S36. Go to original source... Go to PubMed...
  21. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428. Go to original source... Go to PubMed...
  22. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68: 14-22. Go to original source... Go to PubMed...
  23. Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1548-1592. Go to original source... Go to PubMed...
  24. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98: 59K-77K. Go to original source... Go to PubMed...
  25. Marenzi G, et al. N-Acetylcysteine and Contrast-Induced Nephrophaty in Primary Angioplasty. N Engl J Med 2006; 354: 2773-2782. Go to original source... Go to PubMed...
  26. Izzedine H, et al. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45: 804-817. Go to original source... Go to PubMed...
  27. Taguchi T, et al. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 2005; 148: 107-121. Go to original source... Go to PubMed...
  28. Markowitz GS, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289. Go to original source... Go to PubMed...
  29. Rosner MH, Okusa MD. Drug-associated acute kidney injury in the intensive care unit. Clinical Nephrotoxins, Renal Injury from Drugs and Chemicals (Eds.) 2008. Hardcover. 29-41. Go to original source...
  30. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60: 804-817. Go to original source... Go to PubMed...
  31. López B, Durán G, Vicens G Munar V, et al. Severe tubulo-interstitial nephritis secondary to 5-ASA. Gastroenterol Hepatol 2009; 32(1): 29-31. Go to original source... Go to PubMed...
  32. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solution. Am J Kidney Dis 2008; 51: 491-503. Go to original source... Go to PubMed...
  33. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med 2004; 116(8): 546-554. Go to original source... Go to PubMed...
  34. Uibu T. Retroperitoneal fibrosis: a new asbestos-related disease? Current Medical Literature: Urology 2005; 11(1): 1-5.
  35. Markowitz GS, et al. Lithium nephrotoxicity: a progresive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11: 1439-1448. Go to original source... Go to PubMed...
  36. Olyaei AJ, et al. Nephrotoxicity od immunosupreive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384-389. Go to original source... Go to PubMed...
  37. De Broe ME, et al. Analgesic nephropathy. Nephrol Dial Transplant 1996; 11: 2407-2408. Go to original source... Go to PubMed...
  38. Vadivel N, et al. Analgesic nephropathy. Kidney International 2007; 72(4): 517-520. Go to original source... Go to PubMed...
  39. Mihatsch M, Khanlari B, Brunner FP. Obituary to analgesic nephropathy - an autopsy study. Nephrol Dial Trasnplant 2006; 21: 3139-3145. Go to original source... Go to PubMed...
  40. Michielsen P, Heinemann L, Mihatsch M, Schnülle P, Graf H, Koch KM. Non-phenacetin analgesics and analgesic nephropathy: clinical assessment of high users from a case-control study. Nephrol Dial Trasnplant 2009; 24(4): 1253-1259. Go to original source... Go to PubMed...
  41. H-L Loh A, Cohen AH. Drug-induced kidney disease - pathology and current concepts, review article. Annals Academy of Medicine 2009; 38: 240-250. Go to original source...
  42. Tesař V. Novinky v diagnostice a léčbě glomerulonefritidy. Postgraduální medicína 2013; 15(6): 600-605.
  43. James CW, Steinhaus MC, Szabo S, et al. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004; 24: 415-418. Go to original source... Go to PubMed...
  44. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73: 863-869. Go to original source... Go to PubMed...
  45. De Geus HRH, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J 2012; 5: 102-108. R Go to original source... Go to PubMed...
  46. Hab WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human proximal tubule injury. Kidney Int 2002; 62: 237-244. Go to original source... Go to PubMed...
  47. Parikh CR, Jani A, Melnikov VY, et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004; 43: 405-414. Go to original source... Go to PubMed...
  48. Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010; 36: 444-451. Komentář Matějovič M. Go to original source... Go to PubMed...
  49. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insuficiency. JAMA 2001; 286: 2839-2844. Go to original source... Go to PubMed...
  50. Nash IS, Rojas M, Hebert P, et al. Reducing excessive medication administrativ in hospitalized adults with renal dysfunction. Am J Med Qual 2005; 20: 64-69. Go to original source... Go to PubMed...
  51. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacist and inpatient medical care. A systematic review. Arch Intern Med 2006; 166: 955-964. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.